In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Cerenis Therapeutics SA (cardiovascular and metabolic conditions) has raised €40mm ($51.9mm) through the first closing of its Series C venture round. The Fund for Strategic Investment provided €20mm and the remainder came from current shareholders Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, EDF Ventures, OrbiMed, and Daiwa Corporate Investment. The money will be used to continue developing Phase II CER001 for cardiovascular disease and to work on other HDL drug candidates. The same day it announced the Series C round, Cerenis received €10.7mm from the French government.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?